Zielgerichtete Agonisten des Glucagon-ähnlichen Peptid-1-Rezeptors für Multiple Sklerose (TAG-MS)
TAG-MS: Eine Phase-2-Studie zur gezielten Aktivierung von Glucagon-like-Peptide-1-Rezeptor-Agonisten bei Multipler Sklerose – randomisiert, doppelblind, mit parallelen Armen
The goal of this clinical trial is to evaluate if the study drug will reduce brain and retinal atrophy by reducing inflammation and subsequently slowing neurodegeneration in people with Multiple Sclerosis. The main outcome for the trial is change in normalized brain parenchymal volume (nBPV), measured by magnetic resonance imaging (MRI).
Researchers will compare outcomes from participants randomized to the study drug, versus participants randomized to placebo, to see if there are signs of slowed neurodegeneration (i.e., reduction in brain and retinal atrophy).
Studienübersicht
Status
Status
Bedingungen
Bedingungen
Intervention / Behandlung
Intervention / Behandlung
Studientyp
Studientyp
Einschreibung (Geschätzt)
Einschreibung
Phase
Phase
- Phase 2
Kontakte und Standorte
Studienkontakt
Studienkontakt
- Name: Study Manager
- Telefonnummer: 667-306-8153
- E-Mail: mvieira4@jh.edu
Studienorte
-
-
Kansas
-
Kansas City, Kansas, Vereinigte Staaten, 66103
- Rekrutierung
- University of Kansas Medical Center
-
Hauptermittler:
- Sharon Lynch, MD
-
Kontakt:
- Sara Baker
- Telefonnummer: 913-588-6937
- E-Mail: sbaker12@kumc.edu
-
-
Maryland
-
Baltimore, Maryland, Vereinigte Staaten, 21287
- Rekrutierung
- Johns Hopkins University
-
Hauptermittler:
- Ellen Mowry, MD, MCR
-
Kontakt:
- Margaret Vieira
- Telefonnummer: 667-306-8153
- E-Mail: mvieira4@jh.edu
-
-
New York
-
New York, New York, Vereinigte Staaten, 10029
- Rekrutierung
- Mount Sinai School of Medicine
-
Kontakt:
- Susan Filomena
- Telefonnummer: 212-241-4364
- E-Mail: susan.e.filomena@mssm.edu
-
-
Teilnahmekriterien
Zulassungskriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- Diagnosis of MS (2024 criteria); clinically stable on MS therapy for ≥12 months without relapse or new lesions on brain MRI
- Aged 18-60 years
- Body mass index ≥27.0 kg/m2
Exclusion Criteria:
-
No GLP-1RA or GIP/GLP-1 RA in past year; no known hypersensitivity to medication class
-
No known Barrett's esophagus/gastroesophageal reflux disease, pancreatitis (including past), or gastroparesis
-
No personal/family history of medullary thyroid carcinoma or history of multiple endocrine neoplasia syndrome type 2
-
No chronic kidney disease (estimated glomerular filtration rate ≤50 mL/min) in past year, type 1 diabetes, known diabetic retinopathy, use of insulin or insulin-inducing medications*, dipeptidyl peptidase IV inhibitors**, or warfarin; current/active alcohol or illicit substance abuse
-
No concerns about candidacy of individual on part of person's neurologist or study team clinicians
-
Current or planned (next 2 years) pregnancy/breastfeeding; if able to become pregnant, agree to reliable contraception (contraception requirements as discussed below)***
- currently-approved: Lispro, Aspart, Glulisine, Afrezza, Regular, Concentrated Regular, or Novolin, Velosulin, NPH, glargine, detemir, degludec, and premixed; approved secretagogues: sulphonylureas (e.g. glipizide (± metformin), glyburide (± metformin), glimepiride, pioglitazone/glimepiride) & meglitinide analogues (nateglinide and repaglinide); ** currently-approved:sitagliptin, saxagliptin, linagliptin, alogliptin ***Contraception: Participants of childbearing potential (participant has a uterus and is pre-menopausal) must agree to use contraception, using either one method with a failure rate of <1%/year, or two methods of lesser effectiveness:
Contraceptive methods with a failure rate of < 1% per year includes the following:
- Combined (estrogen and progesterone containing) hormonal contraception (vaginal ring, birth control patch) or progesterone-only hormonal contraception (birth control injections, intrauterine device (IUD), or hormone-releasing implant), or copper IUD
- Complete abstinence from sexual encounters with a person who has testes
Those who do not wish to use one of the above methods of contraception must use two methods. Options include:
-
Oral hormonal contraception plus one barrier method during sexual encounter with a person who has testes (below). While typically oral hormonal contraception has a low failure rate, it is possible that the absorption of contraceptive pills taken by mouth will be impacted by the study drug and thus lower contraceptive effectiveness. Thus, people using pills as primary contraception must, during asexual encounter with a person who has testes, use a second form of barrier contraceptive (below) or must change to one of the other contraceptive methods listed above.
-
Two forms of barrier contraception during sexual encounter with a person who has testes. Examples of barrier contraceptive methods include the following:
-
A condom with or without spermicide
-
A cap, diaphragm, or sponge with or without spermicide
- Periodic abstinence (e.g., calendar, ovulation, symptothermal, or postovulation methods) and withdrawal are not acceptable methods of contraception.
-
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Vervierfachen
Anzahl der Arme
Waffen und Interventionen
Teilnehmergruppe / ArmTeilnehmergruppe / Arm |
Intervention / BehandlungIntervention / Behandlung |
|---|---|
|
Placebo-Komparator: Placebo
|
Placebo (saline solution) |
|
Aktiver Komparator: NLY01 (Study Drug)
5 mg subcutaneous weekly for the first 4 weeks, then 10 mg subcutaneous weekly, with pre-planned dose adjustments if adverse events prevent full dosage. |
NLY01 is a pegylated exenatide |
Was misst die Studie?
Primäre Ergebnismessungen
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Change in normalized (for head size) brain parenchymal volume (nBPV)
Zeitfenster: Baseline, week 48, and week 96
|
Change in normalized (for head size) nBPV (mL). Measured from randomization to end of treatment (approximately 96 weeks). Presented as mean and standard deviation |
Baseline, week 48, and week 96
|
Sekundäre Ergebnismessungen
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Change in normalized gray matter volume (mL)
Zeitfenster: Baseline, week 48, and week 96
|
Presented as mean and standard deviation Measured from randomization to end of treatment (approximately 96 weeks). |
Baseline, week 48, and week 96
|
|
Change in thalamic volume (mL)
Zeitfenster: Baseline, week 48, and week 96
|
Measured from randomization to end of treatment (up to 96 weeks). Presented as mean and standard deviation. |
Baseline, week 48, and week 96
|
|
Change in cortical thickness (mm)
Zeitfenster: Baseline, week 48, and week 96
|
Measured from randomization to end of treatment (approximately 96 weeks), Presented as mean and standard deviation. |
Baseline, week 48, and week 96
|
|
Change in retinal nerve fiber layer thickness
Zeitfenster: Baseline, week 48, and week 96
|
Measured in μm, from randomization to end of treatment (approximately 96 weeks), |
Baseline, week 48, and week 96
|
|
Change in ganglion cell/inner plexiform thickness
Zeitfenster: Baseline, week 48, and week 96
|
Measured in μm, from randomization to end of treatment (approximately 96 weeks), |
Baseline, week 48, and week 96
|
|
Disability progression as assessed by the Expanded Disability Status Scale (EDSS)
Zeitfenster: Approximately every 24 weeks, up to 96 weeks
|
Expanded Disability Status Scale (EDSS). Scale range 0-10; higher score is worse disability progression |
Approximately every 24 weeks, up to 96 weeks
|
|
Disability progression as assessed by the Multiple Sclerosis Functional Composite (MSFC)
Zeitfenster: Approximately every 24 weeks, up to 96 weeks
|
The Multiple Sclerosis Functional Composite (MSFC) calculates a single Z-score from tests of ambulation, arm dexterity, and cognition. Scores are converted to a z score with a mean and standard deviation. A higher Z-score indicates better function. |
Approximately every 24 weeks, up to 96 weeks
|
|
Disability progression as assessed by the Expanded Disability Status Scale-Plus
Zeitfenster: Approximately every 24 weeks, up to 96 weeks
|
The EDSS-plus allows for documentation of progression as a composite value, considering progression as having occurred if any one of the following occurs: 20% increase in timed 25-foot walk or 9-hole peg test, or a 1.0-point increase in EDSS (if baseline is 5.5 or less) or a 0.5-point increase (if baseline is >5.5). |
Approximately every 24 weeks, up to 96 weeks
|
|
Patient-reported disability progression as assessed by the Patient-Determined Disease Steps
Zeitfenster: Approximately every 24 weeks, up to 96 weeks
|
Patient-Determined Disease Steps score range 0-8; higher is worse progression |
Approximately every 24 weeks, up to 96 weeks
|
|
Change in self-reported anxiety as assessed by the Quality of Life in Neurological Disorders (Neuro-QOL) Anxiety Subscale
Zeitfenster: Approximately every 24 weeks, up to 96 weeks
|
Quality of Life in Neurological Disorders (Neuro-QOL) Anxiety Subscale. Higher scores indicate more of the domain; distribution of T-Score has a mean of 50, standard deviation of 10. |
Approximately every 24 weeks, up to 96 weeks
|
|
Change in self-reported depression as assessed by the Quality of Life in Neurological Disorders (Neuro-QOL) Depression Subscale
Zeitfenster: Approximately every 24 weeks, up to 96 weeks
|
Quality of Life in Neurological Disorders (Neuro-QOL) Depression Subscale. Higher scores indicate more of the domain; distribution of T-Score has a mean of 50, standard deviation of 10. |
Approximately every 24 weeks, up to 96 weeks
|
|
Change in self-reported fatigue as assessed by the Quality of Life in Neurological Disorders (Neuro-QOL) Fatigue Subscale
Zeitfenster: Approximately every 24 weeks, up to 96 weeks
|
Quality of Life in Neurological Disorders (Neuro-QOL) Fatigue Subscale. Higher scores indicate more of the domain; distribution of T-Score has a mean of 50, standard deviation of 10. |
Approximately every 24 weeks, up to 96 weeks
|
|
Change in self-reported upper extremity function as assessed by the Quality of Life in Neurological Disorders (Neuro-QOL) Upper Extremity Function Subscale
Zeitfenster: Approximately every 24 weeks, up to 96 weeks
|
Quality of Life in Neurological Disorders (Neuro-QOL) Upper Extremity Function Subscale. Higher scores indicate more of the domain; distribution of T-Score has a mean of 50, standard deviation of 10. |
Approximately every 24 weeks, up to 96 weeks
|
|
Change in self-reported lower extremity function as assessed by the Quality of Life in Neurological Disorders (Neuro-QOL) Lower Extremity Function Subscale
Zeitfenster: Approximately every 24 weeks, up to 96 weeks
|
Quality of Life in Neurological Disorders (Neuro-QOL) Lower Extremity Function Subscale. Higher scores indicate more of the domain; distribution of T-Score has a mean of 50, standard deviation of 10. |
Approximately every 24 weeks, up to 96 weeks
|
|
Change in self-reported cognitive function as assessed by the Quality of Life in Neurological Disorders (Neuro-QOL) Cognitive Function Subscale
Zeitfenster: Approximately every 24 weeks, up to 96 weeks
|
Quality of Life in Neurological Disorders (Neuro-QOL) Cognitive Function Subscale. Higher scores indicate more of the domain; distribution of T-Score has a mean of 50, standard deviation of 10. |
Approximately every 24 weeks, up to 96 weeks
|
|
Change in positive affect/well-being as assessed by the Quality of Life in Neurological Disorders (Neuro-QOL) Positive Affect/Well-being Subscale
Zeitfenster: Approximately every 24 weeks, up to 96 weeks
|
Quality of Life in Neurological Disorders (Neuro-QOL) Positive Affect/Well-being Subscale. Higher scores indicate more of the domain; distribution of T-Score has a mean of 50, standard deviation of 10. |
Approximately every 24 weeks, up to 96 weeks
|
|
Change in self-reported sleep disturbance as assessed by the Quality of Life in Neurological Disorders (Neuro-QOL) Sleep Disturbance Subscale
Zeitfenster: Approximately every 24 weeks, up to 96 weeks
|
Quality of Life in Neurological Disorders (Neuro-QOL) Sleep Disturbance Subscale. Higher scores indicate more of the domain; distribution of T-Score has a mean of 50, standard deviation of 10. |
Approximately every 24 weeks, up to 96 weeks
|
|
Change in self-reported ability to participate in social roles Quality of Life in Neurological Disorders (Neuro-QOL) Ability to Participate in Social Roles Subscale
Zeitfenster: Approximately every 24 weeks, up to 96 weeks
|
Quality of Life in Neurological Disorders (Neuro-QOL) Ability to Participate in Social Roles Subscale. Higher scores indicate more of the domain; distribution of T-Score has a mean of 50, standard deviation of 10. |
Approximately every 24 weeks, up to 96 weeks
|
|
Change in self-reported stigma as assessed by the Quality of Life in Neurological Disorders (Neuro-QOL) Stigma Subscale
Zeitfenster: Approximately every 24 weeks, up to 96 weeks
|
Quality of Life in Neurological Disorders (Neuro-QOL) Stigma Subscale. Higher scores indicate more of the domain; distribution of T-Score has a mean of 50, standard deviation of 10. |
Approximately every 24 weeks, up to 96 weeks
|
|
Adverse events
Zeitfenster: From randomization to week 96
|
Proportion of individuals in each arm experiencing adverse events |
From randomization to week 96
|
|
Serious adverse events
Zeitfenster: From randomization to week 96
|
Proportion of individuals in each arm experiencing serious adverse events |
From randomization to week 96
|
Mitarbeiter und Ermittler
Sponsor
Sponsor
Mitarbeiter
Mitarbeiter
Ermittler
Ermittler
- Hauptermittler: Ellen M Mowry, MD, MCR, Johns Hopkins University
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Studienbeginn
Primärer Abschluss (Geschätzt)
Primärer Abschluss
Studienabschluss (Geschätzt)
Studienabschluss
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Zuerst gepostet
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes Update gepostet
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
Andere Studien-ID-Nummern
- IRB00454859
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Beschreibung des IPD-Plans
De-identified individual participant data (IPD) that underlie the results reported in this publication, along with the protocol and analysis plan, will be available upon reasonable request to qualified researchers. Requests must include a proposal and are contingent on meeting regulatory approvals, including a signed data use agreement.
IPD-Sharing-Zeitrahmen
Data will be available 6 months after publication and remain accessible for 12-24 months.
IPD-Sharing-Zugriffskriterien
Qualified researchers who have completed and signed approvals for data sharing.
Art der unterstützenden IPD-Freigabeinformationen
- STUDIENPROTOKOLL
- SAFT
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .